Erin Quirk, M.D. is President, Chief Medical Officer, and Head of Research & Development at Terns Pharmaceuticals, a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH).
She previously served as Vice President of HIV Clinical Research at Gilead Sciences where she contributed to the development and registration of multiple medicines for HIV. She started her pharmaceutical industry career at Merck where she worked on the development of new therapies for chronic hepatitis C infection. Dr. Quirk received her undergraduate degree in Biology and English Literature from Drew University and her M.D. from the University of Colorado School of Medicine. She completed her Residency in Internal Medicine and a Fellowship in Infectious Diseases at Barnes-Jewish Hospital, Washington University in St. Louis, MO.
